- Home
- TVTX vs BHVN Comparison
TVTX vs BHVN Comparison
Compare TVTX & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- BHVN
- Stock Information
- Founded
- TVTX 2008
- BHVN 2013
- Country
- TVTX United States
- BHVN United States
- Employees
- TVTX N/A
- BHVN N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- TVTX Health Care
- BHVN Health Care
- Exchange
- TVTX Nasdaq
- BHVN Nasdaq
- Market Cap
- TVTX 1.5B
- BHVN 1.5B
- IPO Year
- TVTX N/A
- BHVN 2017
- Fundamental
- Price
- TVTX $23.36
- BHVN $13.86
- Analyst Decision
- TVTX Strong Buy
- BHVN Strong Buy
- Analyst Count
- TVTX 16
- BHVN 15
- Target Price
- TVTX $35.07
- BHVN $56.07
- AVG Volume (30 Days)
- TVTX 2.6M
- BHVN 2.1M
- Earning Date
- TVTX 10-30-2025
- BHVN 11-11-2025
- Dividend Yield
- TVTX N/A
- BHVN N/A
- EPS Growth
- TVTX N/A
- BHVN N/A
- EPS
- TVTX N/A
- BHVN N/A
- Revenue
- TVTX $333,865,000.00
- BHVN N/A
- Revenue This Year
- TVTX $83.26
- BHVN N/A
- Revenue Next Year
- TVTX $43.19
- BHVN $2,002.87
- P/E Ratio
- TVTX N/A
- BHVN N/A
- Revenue Growth
- TVTX 87.94
- BHVN N/A
- 52 Week Low
- TVTX $11.89
- BHVN $12.79
- 52 Week High
- TVTX $28.69
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- TVTX 64.87
- BHVN 40.11
- Support Level
- TVTX $20.84
- BHVN $13.63
- Resistance Level
- TVTX $28.69
- BHVN $17.05
- Average True Range (ATR)
- TVTX 1.44
- BHVN 0.87
- MACD
- TVTX 0.62
- BHVN -0.23
- Stochastic Oscillator
- TVTX 56.60
- BHVN 3.87
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.